Biopharma sales slightly lower than expected at Novo Nordisk

While Novo Nordisk increased its biopharma sales in 2021 compared to 2020, the Danish pharmaceutical giant did not manage to beat the estimations made by analysts.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

Novo Nordisk’s biopharma arm saw sales grow to DKK 4.7bn (USD 713.9m) in the fourth quarter of 2021, up from DKK 4.4bn (USD 668.35m) the same period last year, according to Novo’s financial figures, which were released on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading